Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05066178

Speech Treatment for Minimally Verbal Children With ASD and CAS

Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.

Recruiting

Interested in participating?

Request Info

Key information

Age range

5 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

MGH Institute of Health Professions

Boston, Massachusetts, 02129, United States

Location status: Recruiting

Location contact

Karen Chenausky, PhD

CONTACT

[email protected]

Karen V Chenausky, PhD

PRINCIPAL_INVESTIGATOR

Steve Meyer

CONTACT

[email protected]

617-726-2405

About this study

Although one in four children with autism remain minimally verbal past age five, not all the factors that limit spoken language in these minimally verbal children are known. One powerful contributor may be a motor speech disorder, Childhood Apraxia of Speech (CAS). CAS is an impairment in the ability to plan and sequence for speech, which makes speech inconsistent and imprecise. This project proposes to investigate whether CAS makes the speech of minimally verbal children with autism unintelligible, and then to test whether treating the CAS improves children's speech.

First, a cohort of 20 minimally verbal children with both autism and CAS is identified. The prediction is that the more severe the CAS, the more inconsistent and imprecise a child's speech, and therefore the lower their intelligibility will be. Then, a set of mono- and bisyllabic words is selected that contain the disordered movements that each child shows and use those in treatment.

Treatment will take the form of 15 one-hour sessions where speech practice is embedded in a naturalistic, play-based milieu that is centered on each child's own developmental level. It will involve principles of motor learning (intensive practice of a few words, sometimes all in a row and sometimes mixed up). Different types of cues (touch cues, simultaneous production, etc.) will also be employed to help children say their words correctly, fading back these supports as the child's speech improves. Both of these techniques have been shown to be effective for treating CAS.

Our outcome measures will include both (1) "by-ear" assessments of intelligibility and (2) acoustic and kinematic measurements of children's speech after 15 treatment sessions. The findings will inform clinical practice for minimally verbal children with autism and may lead to the development of novel interventions for this severely affected population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meets criteria for Autism Spectrum Disorder
  • Able to correctly repeat at least 2 syllables
  • Meets criteria for Childhood Apraxia of Speech
  • Lives in an environment where child is exposed to English at least 50% of the time

Exclusion criteria

  • Poorly controlled seizures
  • Factors such as blindness or deafness that contribute to minimally verbal status
  • Lives in an environment where English is not spoken at least 50% of the time
  • Child experiences behavioral challenges that preclude participation in the study

Treatment and study plan

CAS Treatment for Minimally Verbal Children with Autism

Behavioral

Treatment involves principles of motor learning embedded in a naturalistic developmental milieu

Primary outcomes

  1. Attempts Correct

    Time frame: 5 weeks

    Number or percent of target items that were produced correctly

  2. Phonemes Correct

    Time frame: 5 weeks

    Number or percent of phonemes (vowels, consonants) in the target items that were produced correctly

Secondary outcomes

  1. Lip aperture movement variability

    Time frame: 5 weeks

    Amount of variability in lip opening area during production of multiple attempts at the same target

  2. Phoneme distinctiveness

    Time frame: 5 weeks

    Acoustic distinctiveness of different phonemes

Study contacts

Contact information is provided by the study sponsor or research team.

Karen V Chenausky, Ph.D.

CONTACT

[email protected]

617-726-2405

Michael Moody

CONTACT

[email protected]

617-643-4658

Sponsors and collaborators

Lead sponsor

MGH Institute of Health Professions

Other

Registry information

Acronym: TxMVASD+CAS

Important dates

Study start
2024
Primary completion
2030
Study completion
2030
First posted
Oct 4, 2021
Registry last updated
Mar 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.